[1]
|
Kurman RJ, Carcangiu ML, Herrington CS, eds. World Health Organization Classification of Tumours[M]. 4 ed. Lyon:International Agency for Research on Cancer, 2014. |
[2]
|
Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases[J]. Am J Surg Pathol, 1996, 20:1331-1345. doi: 10.1097/00000478-199611000-00004 |
[3]
|
Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma[J]. Am J Surg Pathol, 2010, 34:627-635. doi: 10.1097/PAS.0b013e3181da7687 |
[4]
|
Barcena C, Oliva E. WT1 expression in the female genital tract[J]. Adv Anat Pathol, 2011, 18:454-465. doi: 10.1097/PAP.0b013e318234aaed |
[5]
|
Escobar J, Klimowicz AC, Dean M, et al. Quantification of ER/PR expression in ovarian low-grade serous carcinoma[J]. Gynecol Oncol, 2013, 128:371-376. doi: 10.1016/j.ygyno.2012.10.013 |
[6]
|
Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma[J]. J Natl Cancer Inst, 2003, 95:484-486. doi: 10.1093/jnci/95.6.484 |
[7]
|
Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations[J]. J Pathol, 2012, 226:413-420. doi: 10.1002/path.3967 |
[8]
|
Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma:pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems[J]. Adv Anat Pathol, 2009, 16:267-282. doi: 10.1097/PAP.0b013e3181b4fffa |
[9]
|
Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory[J]. Am J Surg Pathol, 2010, 34:433-443. doi: 10.1097/PAS.0b013e3181cf3d79 |
[10]
|
Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas[J]. Cancer Res, 2009, 69:4036-4042. doi: 10.1158/0008-5472.CAN-08-3913 |
[11]
|
Hannibal CG, Vang R, Junge J, et al. A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002:Centralized pathology review and overall survival compared with the general population[J]. Gynecol Oncol, 2014, 134:267-273. doi: 10.1016/j.ygyno.2014.06.002 |
[12]
|
Roma A, Malpica A, Deavers M, et al. Ovarian serous borderline tumors with a predominant micropapillary pattern are aggresslve neoplasms with an increased risk of low grade serous carcinoma[J]. Modern Pathol, 2008, 21:221A. |
[13]
|
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline), Ovarian Cancer, Version 2.2015[EB/OL].[2015-07-10]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. |